公开(公告)号：US20240000728A1

公开(公告)日：2024-01-04

申请号：US18347393

申请日：2023-07-05

申请人： Janssen Pharmaceuticals, Inc

发明人： Wayne Drevets ,  Honglan Li ,  David Wood Hough ,  Jaskaran Singh ,  Ewa Wajs

IPC分类号： A61K31/135 ,  A61P25/24 ,  A61K9/00

CPC分类号： A61K31/135 ,  A61P25/24 ,  A61K9/0043 ,  A61K9/0053

摘要： The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

公开(公告)号：US20210386688A1

公开(公告)日：2021-12-16

申请号：US16956403

申请日：2018-12-18

申请人： Janssen Pharmaceuticals, Inc,

发明人： Carla Canuso ,  Wayne Drevets ,  Honglan Li ,  David Wood Hough ,  Adam Janik ,  Rachel Ochs-Ross ,  Jaskaran Singh ,  Ewa Wajs ,  Peter Zannikos

IPC分类号： A61K31/135 ,  A61K9/00 ,  A61P25/24

摘要： The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

公开(公告)号：US11707440B2

公开(公告)日：2023-07-25

申请号：US16956403

申请日：2018-12-18

申请人： Janssen Pharmaceuticals, Inc.

发明人： Wayne Drevets ,  Honglan Li ,  David Wood Hough ,  Jaskaran Singh ,  Ewa Wajs

IPC分类号： A61K31/135 ,  A61P25/24 ,  A61K9/00

CPC分类号： A61K31/135 ,  A61K9/0043 ,  A61K9/0053 ,  A61P25/24

摘要： The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.